Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract Infection
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to learn how effective and safe FP01 lozenges are when
given to subjects with a cough due to an upper respiratory tract infection. The study will
include subjects who have an upper respiratory tract infection, with a cough of less than six
weeks duration.
Phase:
Phase 2
Details
Lead Sponsor:
Cerecor Inc
Treatments:
Antitussive Agents Chlorpheniramine, phenylpropanolamine drug combination Guaifenesin Phenylpropanolamine